Skip to main content
SpringerLink
Log in

Prior authorisation for PCSK9 inhibitors raises concerns

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Doshi JA, et al. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers. Circulation: Cardiovascular Quality and Outcomes : 11 Jan 2018. Available from: URL: https://doi.org/10.1161/CIRCOUTCOMES.117.003939.

  2. Jackevicius CA. Elephant in the Room. Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. Circulation: Cardiovascular Quality and Outcomes : 11 Jan 2018. Available from: URL: https://doi.org/10.1161/CIRCOUTCOMES.117.004425.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prior authorisation for PCSK9 inhibitors raises concerns. PharmacoEcon Outcomes News 795, 25 (2018). https://doi.org/10.1007/s40274-018-4663-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4663-2

Search

Navigation